Fig. 2: Trifluoperazine corrects FXS- and autism-associated behavioral symptoms in Fmr1 KO mice.
Trifluoperazine (TFP, at 0.05 mg/kg) or vehicle (Veh) was administered into wild type (WT) and Fmr1 KO mice (Fmr1) 1 h before testing (a–d). a, b TFP improves sociability in Fmr1 KO and does not affect WT mice. c The percentage of fully buried marbles and marbles on the surface (as indicated) was determined for WT and Fmr1 KO mice following TFP or vehicle administration. d TFP corrects the increased locomotive transition between the lit and dark chamber in Fmr1 KO mice. The total number of entries to the lit chamber was scored. e Mice were injected with vehicle or trifluoperazine 60 min before passive avoidance training. Mice were tested 24 h after training, and crossover latency was scored. f Mice were injected with vehicle or trifluoperazine 60 min after passive avoidance training. Mice were tested 24 h after training, and crossover latency was scored. There is no difference in crossover latency among the four groups during training (genotype effect: F1,36 = 3.218, p = 0.081; drug effect: F1,36 = 0.309, p = 0.581; genotype × drug interaction: F1,36 = 1.256, p = 0.270). Fmr1 KO mice showed impaired memory and not corrected by trifluoperazine. g Mice received three mild electric foot shocks during passive avoidance training. Mice were tested 24 h after training, and crossover latency was scored. a–d p values between the indicated two groups were determined by two-way ANOVA followed by Holm-Sidak test. e, f Two-way ANOVA and Fisher’s exact test was used to analyze training and testing data, respectively. g Student’s t-test and Fisher’s exact test was used to analyze training and testing data, respectively.
